Open Nav

Socium Therapeutics, Inc.

  • Timothy Salmon, Socium Therapeutics, Inc.

Series A ($7M) funding for Phase I trial

  • Date:Thursday, October 18
  • Time:2:45 PM - 3:00 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Socium Therapeutics is developing an orally administered immunotherapy platform based on recombinant Salmonella typhi Ty21a, the same strain that has been used as the typhoid vaccine since 1989. Socium’s patented platform – CReST™ (Cross-Presenting Recombinat Salmonella typhi Ty21a) – induces an innate immune response from Salmonella pathogenesis and an adaptive immune response by cross-presenting tumor-specific antigen to enhance activation of killer T-cells. Socium is advancing its lead candidate in metastatic castration resistant prostate cancer into a Phase I trial.
  • Company
  • Company HQ City:Parsippany
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • CEO/Top Company Official:Timothy M. Salmon
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :SOC-101
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Total Amount Raised to Date, In All Rounds:0
Timothy Salmon
Socium Therapeutics, Inc.